Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 25/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: ClaimsFiler is reminding investors of Pacira BioSciences, Inc. that the lead plaintiff deadline in a securities class action lawsuit is approaching on March 14, 2025. The lawsuit arises from allegations that the company and its executives failed to disclose crucial information during the Class Period from August 2, 2023, to August 8, 2024. Following the company's patent infringement case loss regarding its Exparel product, Pacira's stock price fell sharply, leading to substantial investor losses. The case is currently pending in the United States District Court for the District of New Jersey.

Market Sentiment Analysis

CONCERNS & RISKS

  • Pacira BioSciences is facing a class action lawsuit for failing to disclose material information.
  • The company’s stock price fell over 47% after a significant patent ruling against them.
  • The negative outcome in court regarding the validity of their patent poses serious concerns for revenue.

Full Press Release Details

NEW ORLEANS, March 05, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Pacira investors should visit us at https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything. On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

The deadline to file is March 14, 2025.

What is the class period for the Pacira lawsuit?

The class period is from August 2, 2023, to August 8, 2024.

Where is the Pacira lawsuit filed?

The lawsuit is pending in the U.S. District Court for New Jersey.

What triggered the drop in Pacira's stock price?

The stock fell after the court found a key patent invalid.

How can Pacira investors get more information?

Investors can visit claimsfiler.com or call toll-free at 844-367-9658.

Last updated: Mar 6, 2025